Table 4.

Risk factors of renal survival in myeloperoxidase-ANCA–associated GN

VariablesModel 1Model 2Model 3
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
Hypertension2.39 (1.44 to 3.99)0.001
Hemoglobin, <9 g/dl2.45 (1.53 to 3.89)<0.001
Urinary protein, >1.5 g/24 h1.73 (1.12 to 2.68)0.01
Hypoalbuminemia, <3.5 g/dl2.22 (1.44 to 3.44)<0.0011.85 (1.17 to 2.90)<0.012.11 (1.32 to 3.34)0.002
SCr, ≥4 mg/dl4.62 (2.88 to 7.40)<0.0013.26 (1.99 to 5.34)<0.0012.93 (1.77 to 4.85)<0.001
Renal histologic class<0.001<0.001<0.001
 Sclerotic class1.0 (Reference)1.0 (Reference)1.0 (Reference)
 Mixed class0.32 (0.20 to 0.51)<0.0010.32 (0.20 to 0.52)<0.0010.34 (0.20 to 0.57)<0.001
 Crescentic class0.27 (0.15 to 0.51)<0.0010.26 (0.14 to 0.49)<0.0010.31 (0.16 to 0.59)<0.001
 Focal classa
Chronic tubulointerstitial lesion1.83 (1.38 to 2.42)<0.001
Treatment regimens<0.0010.001
 Glucocorticoids alone1.0 (Reference)1.0 (Reference)
 Glucocorticoids plus MMF0.25 (0.15 to 0.45)<0.0010.32 (0.18 to 0.60)<0.001
 Glucocorticoids plus IV-CTX0.45 (0.27 to 0.75)0.0020.59 (0.34 to 1.03)0.07
  • Model 1: baseline clinical parameters and treatment regimen were assessed as potential confounding factors of histopathologic class in influencing ESRD; the following variables were included: age, sex, duration of renal involvement, hypertension, Birmingham vasculitis activity score, urinary protein, urine red blood cell count, hypoalbuminemia, SCr level, hemoglobin, renal histologic class, chronic tubulointerstitial lesions, treatment regimen (glucocorticoids plus IV-CTX or MMF versus glucocorticoids alone), and additional immunoadsorption/double-filtration plasmapheresis treatment. Only variables with P values <0.10 are showed in model 1. Model 2: adjusted for baseline clinical parameters, including hypertension, hemoglobin, urinary protein, hypoalbuminemia, SCr, renal histologic class, and chronic tubulointerstitial lesion. Model 3: adjusted for covariates from model 2 and treatment regimen. HR, hazard ratio; 95% CI, 95% confidence interval; SCr, serum creatinine; MMF, mycophenolate mofetil; IV-CTX, intravenous cyclophosphamide pulse therapy.

  • a No patients in the focal class progressed to ESRD.